ADCT:NYE-Adc Therapeutics SA (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 4.89

Change

0.00 (0.00)%

Market Cap

USD 0.39B

Volume

0.25M

Avg Analyst Target

USD 22.86 (+367.43%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ADCT Stock Forecast & Price:
Based on the Adc Therapeutics SA stock forecasts from 4 analysts, the average analyst target price for Adc Therapeutics SA is USD 22.86 over the next 12 months. Adc Therapeutics SA’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adc Therapeutics SA is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Adc Therapeutics SA’s stock price was USD 4.89. Adc Therapeutics SA’s stock price has changed by -6.86% over the past week, -35.91% over the past month and -82.71% over the last year.

About Adc Therapeutics SA (ADCT:NYE)

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refrac ...Read More

Company Website : https://www.adctherapeutics.com

Address : Biopole, Epalinges, Switzerland, 1066

Employees : 312

Fiscal Year End : September

Currency: USD

Country : USA

Technical Indicators

Beta : 1.11

52 Week High : 32.00

Short Ratio : 27.76

52 Week Low : 4.73

Shorted Shares : 6,616,934

200 Day Moving Average : 11.86

Shorted Shares Previous Month : 6,893,898

50 Day Moving Average : 7.22

Shares Held By Insiders : 52.35%

Short Percentage : 20.02%

Shares Held by Institutions : 48.51%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

 USD224.72B 32.98 3.07
BHVN Biohaven Pharmaceutical Holdin..

N/A

 USD10.87B N/A -15.28
DNA Ginkgo Bioworks Holdings

N/A

 USD5.25B N/A -1.40
RCUS Arcus Biosciences Inc

N/A

 USD1.82B 25.21 11.38
MYOV Myovant Sciences Ltd

N/A

 USD1.74B N/A -13.33
NUVB Nuvation Bio Inc

N/A

 USD0.44B N/A 1.72
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90
ZYME Zymeworks Inc

N/A

 USD0.33B 300.20 -0.63
LCTX Lineage Cell Therapeutics Inc

N/A

 USD0.20B 3.63 -3.01
ATNM Actinium Pharmaceuticals Inc

N/A

 USD0.18B N/A -2.94

ETFs Containing ADCT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -75.79% 16% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.79% 16% F 2% F
Trailing 12 Months  
Capital Gain -82.71% 25% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.71% 25% F 2% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -26.11% 15% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.11% 15% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 27.62% 85% B 40% F
Risk Adjusted Return -94.52% 9% F 1% F
Market Capitalization 0.39B 83% B 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 85% B 100% A+
Price/Book Ratio 3.41 37% F 23% F
Price / Cash Flow Ratio -1.68 34% F 77% C+
EV/EBITDA -0.82 46% F 79% C+
Management Effectiveness  
Return on Equity -104.08% 23% F 4% F
Return on Invested Capital -64.50% 46% F 5% F
Return on Assets -29.00% 53% F 2% F
Debt to Equity Ratio 75.32% 25% F 46% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 27.76 3% F 0% N/A
Short Percent 20.02% 9% F 20% F
Beta 1.11 50% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.